A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)

2025-522056-10-01 · tracked via the Priya Life Science EU tracker

Sponsor

Vega Therapeutics Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Hemic and Lymphatic Diseases

Decision date

08/12/2025

Enrollment target

Sites

Austria, Italy, Ireland, Germany, Finland

Condition studied

von Willebrand Disease

Investigational medicinal product(s)

VGA039

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Annualized bleeding rate (ABR)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522056-10-01 on CTIS ↗ ← All trials in the EU